Likar Rudolf, Köstenberger Markus, Nahler Gerhard
Abteilung für Anästhesiologie und Intensivmedizin, Klinikum Klagenfurt am Wörthersee, Feschnigstraße 11, 9020, Klagenfurt am Wörthersee, Österreich.
CIS Clinical Investigation Support GmbH, Wien, Österreich.
Schmerz. 2020 Apr;34(2):117-122. doi: 10.1007/s00482-019-00438-9.
Cannabis was used for cancer patients as early as about 2500 years ago. Experimental studies demonstrated tumor-inhibiting activities of various cannabinoids more than 40 years ago. In view of the status of tetrahydrocannabinol (THC) as a regulated substance, non-psychotomimetic cannabidiol (CBD) is of particular importance.
Efficacy of pure CBD in various animal models as well as initial results (case reports) from patients.
Review of the literature on animal experiments and observations in humans.
Preclinical studies, particularly recent ones, including numerous animal models of tumors, unanimously suggest the therapeutic efficacy of CBD. In isolated combination studies, synergistic effects were generally observed. In addition, CBD may potentially play a role in the palliative care of patients, especially concerning symptoms such as pain, insomnia, anxiety, and depression. Further human studies are warranted.
大麻早在约2500年前就被用于癌症患者。40多年前的实验研究表明了各种大麻素的肿瘤抑制活性。鉴于四氢大麻酚（THC）作为一种受管制物质的现状，非精神致幻性的大麻二酚（CBD）尤为重要。
纯CBD在各种动物模型中的疗效以及患者的初步结果（病例报告）。
回顾关于动物实验和人体观察的文献。
临床前研究，尤其是最近的研究，包括众多肿瘤动物模型，一致表明CBD具有治疗效果。在单独的联合研究中，通常观察到协同效应。此外，CBD可能在患者的姑息治疗中发挥作用，特别是在疼痛、失眠、焦虑和抑郁等症状方面。有必要进行进一步的人体研究。
